Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.41 USD
Change Today 0.00 / 0.00%
Volume 0.0
TINLF On Other Exchanges
Symbol
Exchange
TINLF is not on other exchanges.
As of 4:30 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

teijin ltd (TINLF) Snapshot

Open
--
Previous Close
$3.41
Day High
--
Day Low
--
52 Week High
03/6/15 - $3.41
52 Week Low
09/9/14 - $2.39
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
984.8M
EX-Date
09/28/15
P/E TM
--
Dividend
$6.00
Dividend Yield
1.03%
Current Stock Chart for TEIJIN LTD (TINLF)

Related News

No related news articles were found.

teijin ltd (TINLF) Related Businessweek News

No Related Businessweek News Found

teijin ltd (TINLF) Details

Teijin Limited, together with its subsidiaries, provides various solutions in transportation, information and electronics, safety and protection, environment and energy, and healthcare areas in Japan and internationally. The company’s Advanced Fibers and Composites segment offers para-aramid fibers, meta-aramid fibers, carbon fibers, carbon fiber composite materials, artificial leather, polyester fibers, and Polyethylene naphthalate (PEN) fibers. Its Electronics Materials and Performance Polymer Products segment provides polycarbonate resins, PEN resins, polyethylene terephthalate films, PEN films, and processed films. The company’s Healthcare segment offers pharmaceuticals, including Bonalon and Onealfa for the treatment of osteoporosis; Synvisc to treat pain associated with osteoarthritis of the knee; Mucosolvan, an expectorant; Spiropent, a bronchodilator; Atrovent, a prophylaxis for bronchial constriction; Rhinocort for treating allergic rhinitis; Alvesco, an inhaled corticosteroid agent for asthma; Feburic to treat hyperuricemia and gout; Tricor for the treatment of hyperlipidemia; Somatuline to treat acromegaly; Venilon for the severe infectious diseases treatment; Laxoberon, a laxative; and Bonalfa to treat psoriasis. This segment also provides sonic accelerated fracture healing systems, therapeutic oxygen concentrators, and sleep disorder diagnostic systems, as well as non-invasive positive pressure ventilators for sufferers of sleep apnea syndrome. Its Trading and Retail segment sells and trades fibrous raw material, apparel, industrial materials, and performance polymer products. The company also offers IT services in the healthcare field, Web-based enterprise resource planning services, and digital content management services; content distribution services for mobile phones and smartphones, and e-commerce services; and polyester raw materials and polymerization services. Teijin Limited was founded in 1918 and is headquartered in Osaka, Japan.

15,780 Employees
Last Reported Date: 05/8/15
Founded in 1918

teijin ltd (TINLF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teijin ltd (TINLF) Key Developments

Teijin Ltd., Board Meeting, May 08, 2015

Teijin Ltd., Board Meeting, May 08, 2015. Agenda: To consider renewal of former plan with some amendments thereto, in light of the trends in business practice since the introduction of the former plan.

Teijin Limited Announces Dividend for the Second Interim Ended March 31, 2015; Provides Dividend Guidance for the First Interim and Second Interim of the Year Ending March 31, 2016; Reports Consolidated and Company Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for the Interim and for the Year Ending March 31, 2015

Teijin Limited announced a dividend of JPY 2.00 per share for the second interim ended March 31, 2015 against JPY 2.00 per share a year ago. The company provided dividend guidance for the first interim and second interim of 2015. For the first interim, the company provided dividend guidance of JPY 3.00 per share compared to JPY 2.00 per share a year ago. For the second interim of year ending March 31, 2016, the company provided dividend guidance of JPY 3.00 per share. The company reported consolidated and company earnings results for the year ended March 31, 2015. For the year, on consolidated basis, the company reported net sales of JPY 786,171 million, operating income of JPY 39,086 million or net loss of JPY 8,086 million or JPY 8.23 per share against net sales of JPY 784,424 million, operating income of JPY 18,078 million or net income of JPY 8,356 million or JPY 8.50 per share a year ago. The company reported ordinary income of JPY 42,378 million against JPY 19,887 million a year ago. ROE was negative 2.8% against positive 3.0% a year ago. ROA was 5.3% against 2.6% a year ago. Loss before income taxes was JPY 6,927 million against income before income taxes of JPY 14,519 million a year ago. Net cash and cash equivalents provided by operating activities was JPY 76,030 million against JPY 38,586 million a year ago. Purchase of property, plant and equipment was JPY 26,527 million against JPY 30,863 million a year ago. Purchase of intangible assets was JPY 2,364 million against JPY 2,208 million a year ago. Interest-bearing debt was JPY 308.2 billion against JPY 281.5 billion a year ago. Total capital expenditure was JPY 25.3 billion against JPY 30.2 billion a year ago. For the year, on company basis, the company reported net sales of JPY 146,305 million, operating income of JPY 10,970 million or net loss of JPY 4,776 million or JPY 4.86 per share against net sales of JPY 167,711 million, operating income of JPY 3,261 million or net income of JPY 17,540 million or JPY 17.85 per share a year ago. The company reported ordinary income of JPY 20,837 million against JPY 16,018 million a year ago. The company provided earnings guidance for the interim and for the year ending March 31, 2015. For the interim period, the company expects net sales of JPY 400,000 million, operating income of JPY 20,000 million, ordinary income of JPY 21,000, net income of JPY 10,000 and EPS of JPY 10.18. For the year ending March 31, 2015, the company expects net sales of JPY 825,000 million, operating income of JPY 47,500 million, ordinary income of JPY 47,500, net income of JPY 25,000 and EPS of JPY 25.44. The company forecasts ROA of 5.7% and ROE of 8.5%.

Teijin Ltd., 2015 Earnings Call, May 08, 2015

Teijin Ltd., 2015 Earnings Call, May 08, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TINLF:US $3.41 USD 0.00

TINLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celanese Corp $67.85 USD -0.25
Koninklijke DSM NV €53.48 EUR +0.17
LANXESS AG €51.83 EUR -0.061
Mitsui Chemicals Inc ¥411.00 JPY +4.00
Trinseo SA $29.26 USD +0.08
View Industry Companies
 

Industry Analysis

TINLF

Industry Average

Valuation TINLF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEIJIN LTD, please visit www.teijin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.